Losartan and diabetic nephropathy: commentaries on the RENAAL study

AUTOR(ES)

Fisman, Enrique Z

FONTE

BioMed Central

RESUMO

The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy. The primary efficacy measure was the time to the first event of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death. The conclusion was that losartan led to significant improvement in renal outcomes, that was beyond that attributable to blood pressure control in patients with type 2 diabetes and nephropathy.

Documentos Relacionados

• Tobacco and end stage diabetic nephropathy: : Authors' reply
• Efeito da associação de enalapril e losartan sobre proteinúria e marcadores inflamatórios na nefropatia diabética: ensaio clínico em DM tipo 2
• Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review
• The natural course of gold nephropathy: long term study of 21 patients.
• Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist